Arjumand et al. indicated that cervical cancer cells with PIK3CA-E545K mutation are more resistant to cisplatin or cisplatin-based CRT than cells with PIK3CA wild type [115]. This evidence concerns the gene PIK3CA and cervical carcinoma.